Welcome to our dedicated page for EASTMAN CHEMICAL CO SEC filings (Ticker: EMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EASTMAN CHEMICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EASTMAN CHEMICAL CO's regulatory disclosures and financial reporting.
Eastman Chemical reported stronger quarterly results for the period ended June 30, 2026. Second quarter sales were $2,513 million, up from $2,287 million, driven by higher volume/product mix and higher prices, particularly in Advanced Materials and Chemical Intermediates, partly offset by lower Fibers volume. Gross profit rose to $560 million, and EBIT increased to $311 million from $222 million. Net earnings attributable to Eastman were $183 million with diluted EPS of $1.59 versus $1.20 a year earlier; adjusted EPS was $1.97 versus $1.60, helped by lower environmental and restructuring charges and benefits from IEEPA tariff refunds.
For the first six months, sales were $4,690 million versus $4,577 million, but EBIT declined to $499 million from $524 million and net earnings attributable to Eastman fell to $290 million from $322 million; adjusted EPS was $3.06, down from $3.51. Segment performance was mixed: Chemical Intermediates moved from a loss to positive Adjusted EBIT, Advanced Materials and Fibers delivered lower EBIT despite higher or stable sales, and Additives & Functional Products was broadly steady.
Cash from operating activities for the first six months was $87 million, modestly above the prior-year $66 million, as working capital absorbed cash. Capital expenditures were $203 million. Total borrowings were $5,217 million and cash and cash equivalents $691 million at June 30, 2026, with a fully undrawn $1.50 billion revolving credit facility. Environmental reserves totaled $321 million, with remediation spending expected over about 30 years. Common shares outstanding were 114,377,421 at June 30, 2026.
Eastman Chemical Company reported second-quarter 2026 sales revenue of $2,513 million, up 10 percent from $2,287 million a year earlier, driven by 5 percent higher volume/mix, 4 percent higher selling prices and a 1 percent favorable currency impact. EBIT was $311 million versus $222 million, and adjusted EBIT was $320 million versus $275 million. Diluted EPS was $1.59 versus $1.20, with adjusted EPS of $1.97 versus $1.60.
Advanced Materials and Additives & Functional Products each grew sales 5 percent, while Chemical Intermediates sales rose 39 percent and Fibers declined 11 percent. Segment EBIT improved sharply in Chemical Intermediates but decreased in Advanced Materials and Fibers. Net cash provided by operating activities was $224 million versus $233 million, and the company returned $96 million to stockholders through dividends. Net debt was $4,526 million at June 30, 2026.
Management highlighted progress toward $125 million to $150 million of cost savings, net of inflation, and expects 2026 capital expenditures of about $400 million. For 2026, operating cash flow is expected to approach $900 million, modestly below the previous outlook, and third-quarter adjusted EPS is projected to approach second-quarter 2026 adjusted EPS of $1.97.
Eastman Chemical Company senior vice president and chief human resources officer Adrian James Holt reported routine equity compensation activity involving restricted stock units. On June 1, 2026, 4,341 restricted stock units granted on June 1, 2023 vested and were settled into an equal number of common shares. To cover tax obligations on this vesting, 1,058 common shares were withheld rather than sold in the open market. After these transactions, Holt directly holds 3,283 shares of Eastman Chemical common stock, and the vested restricted stock unit award has been fully converted into shares.
Eastman Chemical Company reported the results of its 2026 annual shareholder meeting. Of 114,349,911 common shares outstanding, 100,631,008 were represented by proxy or virtually, so business could proceed. Shareholders elected eleven directors to one-year terms and ratified PricewaterhouseCoopers LLP as independent auditor for 2026.
Investors cast an advisory "say-on-pay" vote approving the company’s executive compensation, and also approved the 2026 Omnibus Stock Compensation Plan. A shareholder proposal to lower the ownership threshold for calling special shareholder meetings to 10% did not receive majority support and was not adopted.
Alfonso Humberto P reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Humberto P. Alfonso received a grant of 1,628 Phantom Stock Units on May 7, 2026. These units are part of the Directors' Deferred Compensation Plan and each unit’s value equals one share of Eastman common stock.
The award represents the deferral, at the director’s election, of the value of his annual non-employee director restricted stock award that would otherwise have been paid in common stock. The Phantom Stock Units vest on May 7, 2027 and are payable only in cash. Following this grant, the director holds 57,588 Phantom Stock Units in total.
BEGEMANN BRETT D reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Brett D. Begemann reported a routine compensation transaction involving phantom stock units tied to Eastman Chemical common stock. He received an award of 1,628 Phantom Stock Units, each valued at $73.69, credited under the company’s Directors' Deferred Compensation Plan.
These units are unvested, will vest on May 7, 2027, and are payable only in cash, meaning they do not represent actual shares or voting rights. Following this award, Begemann now holds 60,034 Phantom Stock Units in total, reflecting deferred, cash-settled director compensation rather than an open-market stock purchase.
Mink Kim Ann reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Kim Ann Mink reported receiving a grant of 1,628 Phantom Stock Units tied to the company’s common stock value at $73.69 per unit. This compensation-related award increases her Phantom Stock Unit balance to 17,280 units. The units are unvested, will vest on May 7, 2026, and are payable only in cash under the Directors' Deferred Compensation Plan. The grant reflects her election to defer the value of an annual non-employee director restricted stock award that otherwise would have been paid in common stock.
SLAGER DONALD W reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical Company director Donald W. Slager received an equity grant of 1,628 shares of common stock. This was a grant or award, not an open-market purchase or sale, and carried a price of $0.00 per share as compensation rather than a cash transaction.
The shares are restricted, with restrictions scheduled to lapse on May 7, 2027, subject to conditions tied to his continued service as a director. Following this grant, Slager directly holds a total of 3,303 shares of Eastman Chemical common stock.
Holder Julie Fasone reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Julie Fasone Holder received a grant of 1,628 shares of common stock as a restricted stock award. The shares were granted at no cash cost and will remain restricted until May 7, 2027, contingent on her continued service as a director. Following this award, she directly holds 19,174 shares of Eastman Chemical common stock.
Eastman Chemical Company director Renee J. Hornbaker received a grant of 1,628 shares of common stock as a restricted stock award. The restrictions are scheduled to lapse on May 7, 2027, subject to her continued service as a director. Following this award, she directly holds 25,565 shares, which include 154 shares acquired through automatic dividend reinvestment since May 1, 2025.